Ann: PAT-DX1 Active in Pre-clinical Cancer Models, page-23

Getting press coverage now. See proactive investors link below:

http://www.*.com.au/companies/news/...-on-the-podium-of-asx-top-gainers-183942.html


Patrys Ltd's (ASXAB) shares are up 75% in morning trade at $0.007, following positive pre-clinical data for its lead drug candidate PAT-DX1, a novel first-in-class drug candidate being developed to treat a range of different cancers.
Studies in multiple pre-clinical models of cancer have demonstrated the ability of Patrys’ proprietary humanized antibody, PAT-DX1 to be taken-up and to kill cancer cells.
This confirms the successful humanization and de-immunization of 3E10-derived antibody fragments with conserved structural properties and enhanced in vitro activity.